Child development after Lyme disease during pregnancy
Follows pregnant women with Lyme disease and their babies' development after birth.
Key facts
- Who runs it
- Children's National Research Institute
- Where
- Washington D.C., United StatesSee the site
- Trial code
- Registry title
- Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Jul 2023
- Expected to end
- Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Neurodevelopmental assessments and follow-up
- Record updated
- 16 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant people who have Lyme disease, or Post-Treatment Lyme Disease Syndrome (PTLDS) / Chronic Lyme. Their babies will be followed from birth until age 18 months.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Lyme disease diagnosed during the current pregnancy (any stage), or PTLDS/Chronic Lyme diagnosed within 3 years of the current pregnancy, per CDC criteria. People can join in any trimester.
Main reasons for not taking part
- Not able to understand the study procedures
- Health issues or a metal implant that prevent having an MRI scan
- Not able to complete the study requirements (people who cannot travel can still join remotely)
- Not an English speaker
- Not living in the United States or Canada
This trial only enrols pregnant participants. The registry sentence this rests on: Meet CDC criteria for: (1) clinical and/or laboratory diagnosis of Lyme disease during any stage of current pregnancy, OR (2) clinical diagnosis of PTLDS/Chronic Lyme within 3 years of current pregnancy
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- English speaker
- Currently reside in the United States or Canada
- Meet CDC criteria for: (1) clinical and/or laboratory diagnosis of Lyme disease during any stage of current pregnancy, OR (2) clinical diagnosis of PTLDS/Chronic Lyme within 3 years of current pregnancy
- Able to be contacted for follow-up
Who cannot take part
- Health issues or metallic implant that precludes undergoing MRI
- Intellectually unable to comprehend study procedures
- Incapable of completing study requirements (note: inability to travel to Children's National for in-person follow-up [for example, due to bedrest, travel restrictions, or financial inability to travel] is NOT an exclusion criterion; any interested and eligible participants requiring "remote only" participation will be permitted to join the study and complete all requirements besides in-person follow-up)
Where in United States
- Children's National HospitalWashington D.C., United StatesContact: Meagan Williams, MSPH, CCRCTaking people
About the trial
What the trial wants to find out
The purpose of this pilot study is to assess the feasibility of longitudinal neurodevelopmental evaluation of fetuses and infants exposed to Lyme disease in utero. Participants with Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS) will be recruited during pregnancy. Pregnancies will be monitored and infant development will be assessed from birth until age 18 months.
The 2 groups in the trial
- Lyme disease
Pregnant participants in the "Lyme disease" cohort will meet CDC criteria for clinical and/or laboratory diagnosis of Lyme disease during pregnancy based on stage of disease. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines. Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months.
Treatment: Neurodevelopmental assessments and follow-up
- Post-treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme
Pregnant participants in the "PTLDS/Chronic Lyme" cohort will have been diagnosed with PTLDS/Chronic Lyme by a health care provider no less than 6 months, but no greater than 3 years, prior to enrollment. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines. Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months.
Treatment: Neurodevelopmental assessments and follow-up
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
- Plain-language title
- Child development after Lyme disease during pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 16 June 2026